175 related articles for article (PubMed ID: 25983032)
21. Stem cell marker CD133 affects clinical outcome in glioma patients.
Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
[TBL] [Abstract][Full Text] [Related]
22. Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.
Huang T; Li S; Yang Z; Liu J; Han Y
Mol Neurobiol; 2016 Nov; 53(9):6407-6412. PubMed ID: 26582467
[TBL] [Abstract][Full Text] [Related]
23. The prognostic role of CD133 expression in patients with osteosarcoma.
Xu N; Kang Y; Wang W; Zhou J
Clin Exp Med; 2020 May; 20(2):261-267. PubMed ID: 32048073
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
25. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
26. Older studies can underestimate prognosis of glioblastoma biomarker in meta-analyses: a meta-epidemiological study for study-level effect in the current literature.
Lu VM; Phan K; Yin JXM; McDonald KL
J Neurooncol; 2018 Sep; 139(2):231-238. PubMed ID: 29767813
[TBL] [Abstract][Full Text] [Related]
27. The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence.
Shibahara I; Sonoda Y; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Suzuki H; Watanabe T; Ishioka C; Tominaga T
Neuro Oncol; 2013 Sep; 15(9):1151-9. PubMed ID: 23658323
[TBL] [Abstract][Full Text] [Related]
28. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
[TBL] [Abstract][Full Text] [Related]
29. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
30. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis.
He XY; Liao YD; Guo XQ; Wang R; Xiao ZY; Wang YG
Mol Neurobiol; 2016 Apr; 53(3):1856-1861. PubMed ID: 25790954
[TBL] [Abstract][Full Text] [Related]
32. Expression and regulation of AC133 and CD133 in glioblastoma.
Campos B; Zeng L; Daotrong PH; Eckstein V; Unterberg A; Mairbäurl H; Herold-Mende C
Glia; 2011 Dec; 59(12):1974-86. PubMed ID: 21901757
[TBL] [Abstract][Full Text] [Related]
33. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
[TBL] [Abstract][Full Text] [Related]
35. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
36. Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis.
Madjd Z; Erfani E; Gheytanchi E; Moradi-Lakeh M; Shariftabrizi A; Asadi-Lari M
Int J Biol Markers; 2016 May; 31(2):e118-25. PubMed ID: 27102864
[TBL] [Abstract][Full Text] [Related]
37. CPEB4 regulates glioblastoma cell proliferation and predicts poor outcome of patients.
Wang HX; Qin R; Mao J; Huang QL; Hong F; Li F; Gong ZY; Xu T; Yan Y; Chao SH; Zhang SK; Chen JX
Clin Neurol Neurosurg; 2018 Jun; 169():92-97. PubMed ID: 29642043
[TBL] [Abstract][Full Text] [Related]
38. Down-expression of miR-154 suppresses tumourigenesis in CD133(+) glioblastoma stem cells.
Yang L; Yan Z; Wang Y; Ma W; Li C
Cell Biochem Funct; 2016 Aug; 34(6):404-13. PubMed ID: 27338789
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis.
Li Z; Yin S; Zhang L; Liu W; Chen B; Xing H
Onco Targets Ther; 2017; 10():859-870. PubMed ID: 28243121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
